TransMedics Group’s (TMDX) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a report published on Tuesday morning,Benzinga reports.

Several other brokerages also recently commented on TMDX. TD Cowen reduced their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Oppenheimer lowered their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. JPMorgan Chase & Co. reduced their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research note on Tuesday, October 29th. Finally, Canaccord Genuity Group decreased their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Trading Down 8.3 %

TransMedics Group stock opened at $66.25 on Tuesday. The stock has a 50-day simple moving average of $105.43 and a 200 day simple moving average of $134.42. The stock has a market capitalization of $2.22 billion, a P/E ratio of 70.48 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group has a 52 week low of $66.10 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. The business’s revenue was up 63.7% compared to the same quarter last year. Analysts expect that TransMedics Group will post 1 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,042 shares of company stock worth $3,563,985. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of TMDX. Amalgamated Bank grew its holdings in shares of TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the last quarter. Harbour Capital Advisors LLC increased its position in TransMedics Group by 1.7% in the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after acquiring an additional 81 shares during the period. Signaturefd LLC raised its stake in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. Arizona State Retirement System raised its stake in shares of TransMedics Group by 2.1% during the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after acquiring an additional 186 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its holdings in shares of TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after purchasing an additional 219 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.